Formats
  1. Journal Article (66871)
  2. Meeting Abstract (33621)
  3. Book Section (5097)
  4. Review (3759)
  5. Editorial (2172)
  6. Conference Paper (1526)
  7. Correspondence (666)
  8. Guidelines (662)
  9. Research Letter (548)
  10. Book Whole (344)
  11. Miscellaneous (339)
Groups
  1. Department of Medicine (39065)
  2. GSK Faculty (22476)
  3. Solid Tumor Oncology Division (22077)
  4. Surgery (21270)
  5. Survivorship Research (15773)
  6. Sloan Kettering Institute Faculty (15657)

More Groups

People
  1. Marc Ladanyi (1328)
  2. Robert Motzer (1243)
  3. Victor Reuter (1228)
  4. Howard Scher (1130)
  5. Murray Brennan (1059)
  6. Sergio Giralt (1052)

More People

Years
  1. 2025 (2137)
  2. 2024 (5384)
  3. 2023 (5806)
  4. 2022 (6169)
  5. 2021 (5714)
  6. 2020 (5618)

More Years

Publications
  1. Journal of Clinical Oncology (8590)
  2. Blood (4951)
  3. Cancer Research (2701)
  4. International Journal of Radiation Oncology, Biology, Physics (2611)
  5. Laboratory Investigation (1879)
  6. Modern Pathology (1814)

More Publications

Publishers
  1. Elsevier Inc. (13846)
  2. American Society of Clinical Oncology (9169)
  3. Springer (7194)
  4. Nature Publishing Group (6375)
  5. American Association for Cancer Research (6014)
  6. Elsevier Science, Inc. (5512)

More Publishers

Results (115605)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Universal updated phase 1 data highlights role of allogeneic anti-BCMA ALLO-715 therapy for relapsed/refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Matous, J. V.; Liedtke, M.; Sidana, S.; Oluwole, O. O.; Mohan, M.; Cruz, J. C.; Nath, R.; Anwer, F.; Rossi, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Prognostic impact of comorbidities on outcomes of patients (pts) with relapsed or refractory large B-cell lymphoma (r/r LBCL) treated with chimeric antigen receptor T-cell therapy (CART)
    Meeting Abstract

    Greenbaum, U.; Hashmi, H.; Elsawy, M.; Kim, S.; Moskop, A.; Awan, F. T.; Farooq, U.; Ganguly, S.; Hematti, P.; Jain, M. D.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 1 first-in-human study of Abbv-383, a BCMA x CD3 bispecific T-cell-redirecting antibody, as monotherapy in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Voorhees, P. M.; D'Souza, A.; Weisel, K.; Hurd, D. D.; Teipel, R.; Chung, A.; Rodriguez, C.; Tuchman, S. A.; Korde, N.; Safah, H.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed/refractory multiple myeloma: Early experience from a phase I study
    Meeting Abstract

    Lesokhin, A. M.; Richter, J.; Trudel, S.; Cohen, A. D.; Spencer, A.; Forsberg, P. A.; Laubach, J. P.; Thomas, S. K.; Bahlis, N. J.; Costa, L. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase 2 trial of colesevelam for lenalidomide-associated diarrhea
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Korde, N.; Mailankody, S.; Shekarkhand, T.; Burge, M.; Maclachlan, K. H.; Patel, D.; Shah, U. A.; Chung, D. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Comparing acalabrutinib and ibrutinib in the real world: A study of 2,509 patients with chronic lymphocytic leukemia
    Meeting Abstract

    Roeker, L. E.; DerSarkissian, M.; Ryan, K. J.; Chen, Y.; Wahlstrom, S. K.; Hakre, S.; Yu, L.; Guo, H.; Mato, A. R.
    Blood (2022)

    Fulltext@MSK | Save
  • Initiating first-line (1L) Ibrutinib (Ibr) in patients (pts) with chronic lymphocytic leukemia (CLL) improves overall survival (OS) outcomes to rates approximating an age-matched population of ≥65 years
    Meeting Abstract

    Ghia, P.; Owen, C.; Barrientos, J. C.; Barr, P. M.; Mato, A. R.; Shi, C. X.; Szoke, A.; Abbazio, C.; Krigsfeld, G. S.; Burger, J. A.
    Blood (2022)

    Fulltext@MSK | Save
  • Teclistamab population pharmacokinetics and exposure-response relationship support 1.5 Mg/Kg dose regimen in relapsed/refractory multiple myeloma
    Meeting Abstract

    Miao, X.; Wu, L. S.; Wang Lin, S. X.; Xu, Y.; Chen, Y.; Iwaki, Y.; Kobos, R.; Stephenson, T.; Kemmerer, K.; Uhlar, C. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Stem cell mobilization characteristics for transplant eligible patients with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib, lenalidomide, dexamethasone, and daratumumab (KRd-Dara)
    Meeting Abstract

    Bhutani, M.; Robinson, M.; Atrash, S.; Watts, N.; Paul, B.; Chhabra, S.; Korde, N.; Begic, X.; Foureau, D. M.; Chung, D. J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Mutational profile of children with myeloproliferative neoplasms
    Meeting Abstract

    Rutherford, K.; Farnoud, N.; Krishnan, A.; Rampal, R. K.; Levine, R. L.; Kucine, N.
    Blood (2022)

    Fulltext@MSK | Save